Repurposing Drugs in Controlling Recurrent Platinum-Resistant Clear-Cell Ovarian Cancer (2023)

Peer-Reviewed Study · Sinsuwan W, Norchai P · June 7, 2023

Sinsuwan W et al., 2023-06-07: Case report of a 41-year-old Thai woman with recurrent platinum-resistant clear-cell ovarian cancer treated with a multi-drug repurposing regimen that included mebendazole 500 mg per week. CA-125 fell from 303.6 to 54 U/mL over four months, but overall survival was 8.5 months and progression-free survival 2 months.

mebendazole (500 mg/week)

n/a

Sinsuwan W et al., 2023-06-07: Case report of a 41-year-old Thai woman with recurrent platinum-resistant clear-cell ovarian cancer treated with a multi-drug repurposing regimen that included mebendazole 500 mg per week. CA-125 fell from 303.6 to 54 U/mL over four months, but overall survival was 8.5 months and progression-free survival 2 months. Study type: case report. N=1. Country: Thailand (Dhurakij Pundit University). Dose: mebendazole 500 mg per week, plus simvastatin 20 mg/day, metformin 500 mg/day, niclosamide 2 g/day, loratadine 10 mg/day, itraconazole 100 mg/day and chloroquine 250 mg every other day. Funder: not stated. Conflicts: authors declare no conflicts of interest. Maker: not stated. Comparator: none; patient had failed two courses of chemotherapy. Outcome: tumour markers fell and quality of life improved, but OS 8.5 months and PFS 2 months. Study type: case report.